1398P Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO) von Ernst, S.M., de Bruijn, P., van der Horst, T.E., Paats, M.S., Aerts, J.G., Mathijssen, R.H., Koolen, S.L., Dingemans, A-M.C.

Volltext

1583P Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: A systematic review and meta-analysis von Guchelaar, N.A.D., Nasserinejad, K., Mostert, B., Koolen, S.L., van der Sluis, P.C., Lagarde, S.M., Wijnhoven, B.P.L., Mathijssen, R.H., Noordman, B.J.

Volltext

1142P The influence of food with different fat concentrations on alectinib exposure: A randomized cross-over pharmacokinetic trial von Lanser, D., Veerman, M.G.D., De Leeuw, S., Oomen-de Hoop, E., Paats, M., Koolen, S.L., Dingemans, A-M.C., Mathijssen, R.H.

Volltext

1154P Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors von van Dorst, D., Hofman, M.M., de Waal, R.M., Oomen-de Hoop, E., Joode, K.D., Bins, S., Koolen, S.L., Joosse, A., Versmissen, J., Van der Veldt, A.A.M., Mathijssen, R.H.

Volltext

100P Evaluation of the circulating stromal biomarker VICM reflecting M1-like macrophage activity in metastatic melanoma patients treated with anti-PD-1 therapy von Jensen, C., Hurkmans, D.P., Koolen, S.L., Aerts, J.G., Karsdal, M.A., Mathijssen, R.H., Willumsen, N.

Volltext

1280P Effects of semaglutide on the exposure of alectinib in patients with NSCLC von Lanser, D.A.C., Heersche, N., Oomen-de Hoop, E., Icli, A., de Bruijn, P., Paats, M.S., van Rossum, E., Koolen, S.L., Van Schaik, R., Dingemans, A-M.C., Veerman, M.G.D., Mathijssen, R.H.

Volltext

1335P The relationship between nivolumab pharmacokinetics and cancer cachexia biomarkers in patients with metastatic non-small cell lung cancer (NSCLC) von Hofman, M., Agema, B.C., Degens, J., Hurkmans, D.P., Dumoulin, D.W., Schols, A., Koolen, S.L., Groeneveldt, C., Worp, W.V.D., Hendriks, L.E., Van Der Leest, C.H., Aerts, J.G., Mathijssen, R.H., Dingemans, A-M.C., Langen, R., Bins, S.

Volltext

363P Palbociclib exposure in relation to response and toxicity in patients with advanced breast cancer von Buijs, S.M., Ali, M.I. Mohmaed, Hoop, E. Oomen-de, Braal, C.L., Wortelboer, N., Van Ommen-Nijhof, A., Sonke, G.S., Konings, I.R., Jager, A., Steeghs, N., Siebinga, H., Mathijssen, R.H., Huitema, A.D.R., Koolen, S.L.

Volltext

1184P Improving the tolerability of osimertinib by identifying its toxic limit von Agema, B.C., Veerman, M.G.D., Lanser, D., Steendam, C.M.J., Preijers, T., Van Der Leest, C., Koch, B., Dingemans, A-M.C., Mathijssen, R.H., Koolen, S.L.

Volltext

278P Association between tamoxifen and endoxifen plasma levels and clotting proteins in patients with primary breast cancer von van Dorst, D., Buijs, S.M., Kruip, M.J.H.A., van den Akker, R.F.P., Cheung, K.L., Porrazzo, R., Hoop, E. Oomen-de, Jager, A., Koolen, S.L., Versmissen, J., Danser, J.A.H., Versteeg, H.H., Bos, M.H.A., Mathijssen, R.H.

Volltext

1589P Systemic treatment strategies and outcomes of patients with peritoneal metastases of gastric origin von Guchelaar, N.A.D., Noordman, B.J., Welten, M., van Santen, M., de Neijs, M.J., Koolen, S.L., Verhoeven, R.H.A., Oomen-de Hoop, E., van Laarhoven, H.W.M., de Hingh, I.H.J.T., Creemers, G-J., Mostert, B., Wijnhoven, B.P.L., Mathijssen, R.H.

Volltext

1343P Correlating osimertinib and erlotinib pharmacokinetics with efficacy and toxicity in EGFR-mutated NSCLC patients (START-TKI study) von Veerman, G.D.M., Steendam, C.M.J., Koolen, S.L., Hoop, E. Oomen-de, Dingemans, A-M.C., Aerts, J.G.J.V., Mathijssen, R.H.

Volltext

27P Influence of single nucleotide polymorphisms (SNPs) in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer von Veerman, M.G.D., Boosman, R., Jebbink, M., Oomen-de Hoop, E., van der Wekken, A.J., Bahce, I., Hendriks, L., Steendam, C.M.J., de Jonge, E., Koolen, S.L., van Schaik, R.H.N., Smit, E.F., Dingemans, A-M.C., Huitema, A., Mathijssen, R.H.

Volltext

Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach von Mueller-Schoell, A., Klopp-Schulze, L., Huisinga, W., Joerger, M., Neven, P., Koolen, S.L., Mathijssen, R.H.J., Schmidt, S., Kloft, C.

Volltext

296P - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach von Mueller-Schoell, A., Klopp-Schulze, L., Huisinga, W., Joerger, M., Neven, P., Koolen, S.L., Mathijssen, R.H.J., Schmidt, S., Kloft, C.

Volltext

707P Personalised dosing of oral targeted therapies in oncology: The era of therapeutic drug monitoring von van der Kleij, M.B.A., Guchelaar, N.A.D., Meertens, M., Giraud, E.L., Bleckman, R.F., Imholz, A.L.T., Vulink, A., Otten, H-M.M.B., Smilde, T.J., Los, M., Fiebrich, H-B., Hamberg, P., Lubberman, F.J.E., Koolen, S.L., Gelderblom, H., Reyners, A.K.L., Van Erp, N.P., Mathijssen, R.H., Huitema, A.D.R., Steeghs, N.

Volltext

1863P Incidence and predictors of severe adverse events during anti-PD-1 treatment von Basak, E.A., Vermeer, N.S., Joode, K.D., Hurkmans, D.P., Velthuis, D.E.M., Oomen-de Hoop, E., Schreurs, M.W.J., Bins, S., van der Leest, C., Joosse, A., Koolen, S.L., Debets, R., van der Veldt, A.A.M., Aerts, J.G., Mathijssen, R.H.

Volltext

412P Phase I study of intraperitoneal irinotecan in combination with standard systemic chemotherapy in patients with extensive peritoneal metastases of colorectal origin: The INTER... von Van Eerden, R.A.G., De Boer, N.L., van Kooten, J.P., Bakkers, C., Dietz, M.V., Creemers, G-J.M., Buijs, S.M., Bax, R., de Man, F.M., Lurvink, R.J., Diepeveen, M., Brandt-Kerkhof, A.R.M., van Meerten, E., Koolen, S.L., de Hingh, I.H.J.T., Verhoef, K., Mathijssen, R.H., Burger, P.W.A.

Volltext

Influence of genetic variation in COMT on cisplatin-induced nephrotoxicity in cancer patients von Agema, B.C., Koolen, S.L., De With, M., Heersche, N., van Doorn, N., Oomen-de Hoop, E., Visser, S., Aerts, J.G., Bins, S., van Schaik, R.H.N., Mathijssen, R.H.

Volltext

1893P - Influence of genetic variation in COMT on cisplatin-induced nephrotoxicity in cancer patients von Agema, B.C., Koolen, S.L., De With, M., Heersche, N., van Doorn, N., Oomen-de Hoop, E., Visser, S., Aerts, J.G., Bins, S., van Schaik, R.H.N., Mathijssen, R.H.

Volltext